The story of Sildenafil presents a nuanced case for investors in the medicinal sector. While initially a phenomenal success, producing billions, the patent expiration and the subsequent entry of generic alternatives have significantly changed earnings. This poses questions about the future profitability of analogous drug developments and suggest… Read More